Asian Multicenter Prospective Study in HER2 Positive Early Breast Cancer for Detecting MRD by ctDNA;HARMONY Study

HER2-positive Breast Cancer Clinical Trial

Official title:

Asian Multicenter Prospective Study in HER2 Positive Early Breast Cancer for Detecting Minimal Residual Disease by Circulating Tumor DNA Analysis With Neoadjuvant Chemotherapy; HARMONY Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05433753
• Other study ID #: NCCH2113
• Status: Recruiting
• Start date: May 24, 2022
• Est. completion date: September 30, 2027

Study information

• Verified date: March 2024
• Source: National Cancer Center, Japan
• Contact: Yuki Kojima, MD, PhD
• Phone: 0335422511
• Email: yuukojim[@]ncc.go.jp
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

This study will assess minimal residual disease (MRD) in HER2-positive early breast cancer patients in Asian countries. The purpose is to evaluate the relation between the detection rate of MRD and recurrence.

Description:

This study will evaluate the relation between the detection rate of minimal residual disease(MRD) and recurrence in HER2-positive early breast cancer patients in Asian countries. Blood will be regularly collected to check the presence of ctDNA in HER2-positive breast cancer patients who have scheduled for neoadjuvant chemotherapy followed by surgery. Prognostic data is also collected on the same patients.

MRD is a small number of cancer cells left in the body during or after treatment. These cells have the potential to cause recurrence in cancer patients. MRD detection can help identify patients at increased risk of disease recurrence and guide treatment decisions. However, limited data are available on when ctDNA analysis should be done in the course of treatment, and what is the appropriate analysis method. This study will contribute to determining whether MRD detection using ctDNA is useful to predict the recurrence of HER2-positive early breast cancer patients. If this can be proven, it is expected that detection of MRD can use as a biomarker to assist in the de-/escalation of treatment strategies, therefore allowing to avoid overtreatment in patients at low risk, and to add more intensive treatment in patients at high risk. Moreover, studying with Asian countries, the results will become the basic data for approval of liquid biopsy.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 60
• Est. completion date: September 30, 2027
• Est. primary completion date: September 30, 2027
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years and older

Eligibility

Inclusion Criteria:

1. Age of 20 years or older at the date of registration.

2. Histological diagnosis of HER2-positive invasive breast carcinoma.

3. Patients scheduled for neoadjuvant chemotherapy followed by surgery.

4. Clinical Stage IIA-IIIC.

5. Known hormone receptor status.

6. Signed informed consent.

Exclusion Criteria:

1. Any other malignancy within 5 years prior to registration, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the esophagus, stomach, colon, or cervix.

2. Bilateral synchronous breast cancer.

3. History of breast cancer.

4. Pregnancy at registration.

Related Conditions & MeSH terms

• Breast Neoplasms
• HER2-positive Breast Cancer

Locations

Country	Name	City	State
Japan	National Cancer Center Hospital, Japan	Chuo-ku	Tokyo

Sponsors (1)

Lead Sponsor	Collaborator
National Cancer Center, Japan

Country where clinical trial is conducted

Japan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Invasive disease-free survival (IDFS)	ipsilateral invasive breast cancer recurrence, regional invasive breast cancer recurrence, distant recurrence, death attributable to any cause, contralateral invasive breast cancer	The duration from the date of surgery until the date of first documented the IDFS events, whichever comes first, up to 3 years.
Secondary	Overall survival (OS)	Death attributable to any cause	The duration from the date of surgery until the date of death from any cause, up to 3 years.
Secondary	Disease-free survival (DFS)	IDFS events, ipsilateral or contralateral DCIS, second primary non-breast invasive cancer	The duration from the date of surgery until the date of first documented the DFS events, whichever comes first, up to 3 years.